Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-bli... by Zhu, Andrew X, Dr, Park, Joon Oh, MD, Ryoo, Baek-Yeol, MD, Yen, Chia-Jui, MD, Poon, Ronnie, MD, Pastorelli, Davide, MD, Blanc, Jean-Frederic, MD, Chung, Hyun Cheol, MD, Baron, Ari D, MD, Pfiffer, Tulio Eduardo Flesch, MD, Okusaka, Takuji, MD, Kubackova, Katerina, MD, Trojan, Jorg, MD, Sastre, Javier, PhD, Chau, Ian, MD, Chang, Shao-Chun, MD, Abada, Paolo B, MD, Yang, Ling, MS, Schwartz, Jonathan D, MD, Kudo, Masatoshi, MD

Get full text